Encompass Health Q3 2026 Earnings: EBITDA Growth Outpaces Revenue

Encompass Health (NYSE: EHC) reported Q3 2026 net operating revenue of $1.6095 billion, up 8.9% from $1.4775 billion, while GAAP diluted EPS from continuing operations attributable to the company rose 21.8% to $1.51 from $1.24. For the quarter ended September 30, 2026, adjusted EBITDA increased 15.5% and operating cash flow rose 33.7%, with discharge growth and higher net patient revenue per discharge supporting the result. The company also raised all three of its full-year guidance ranges.

Core Financial Results

Revenue growth reflected both higher patient volume and more revenue per discharge. Total discharges increased 5.7%, while net patient revenue per discharge rose 4.0%.

Profit and cash flow grew faster than revenue. Total operating expenses increased approximately 7.1%, compared with the 8.9% revenue increase, contributing to faster growth in continuing-operations income, adjusted EBITDA, and EPS.

Adjusted EPS, adjusted EBITDA, and adjusted free cash flow are non-GAAP measures. The small difference between reported continuing-operations EPS and adjusted EPS in Q3 2026 primarily reflected a state regulatory change impact.

Patient Volume and Capacity Expansion

Encompass Health recorded 69,605 discharges, up from 65,839 a year earlier. Same-store discharge growth was 3.0%, while net patient revenue per discharge increased to $22,543 from $21,679.

Total discharge growth exceeded same-store growth, consistent with contributions from capacity outside the established same-store base, although the company did not quantify the exact Q3 impact. During the first nine months of 2026, Encompass Health opened four hospitals with 189 beds and added 85 beds to existing hospitals. Those figures cover the nine-month period rather than Q3 alone.

Revenue Growth Outpaced Operating Costs, Expanding Margins

Total operating expenses rose to $1.3215 billion from $1.2339 billion, an increase of approximately 7.1%. Based on reported revenue and operating expenses, implied operating income increased to approximately $288.0 million from $243.6 million, while the implied operating margin expanded to about 17.9% from 16.5%.

The adjusted EBITDA margin also improved to approximately 21.5% from 20.3%, an increase of about 1.2 percentage points. Salaries and benefits remained the largest expense category and increased 7.1% to $840.7 million, but that growth remained below the rate of revenue expansion.

Cash Flow and Balance Sheet

Quarterly operating cash flow increased by $91.2 million to $362.0 million. Adjusted free cash flow rose even faster, supported by higher cash flow from continuing operations and lower maintenance capital expenditures of $56.0 million versus $61.4 million, partly offset by higher distributions to noncontrolling interests.

For the first nine months of 2026, operating cash flow totaled $957.7 million, compared with $829.6 million a year earlier. Purchases of property, equipment, and intangible assets increased to $617.2 million from $507.1 million, reflecting the capital requirements associated with the company’s expanding hospital base.

At September 30, 2026, cash and cash equivalents stood at $76.2 million, compared with $72.2 million at December 31, 2025. Total debt, including the current portion, was approximately $2.60 billion, up from approximately $2.49 billion, while net property and equipment increased to $4.48 billion from $4.10 billion. During the first nine months, the company also spent $203.7 million on share repurchases and paid $57.9 million in common dividends.

2026 Guidance

Encompass Health raised the lower and upper bounds of its full-year revenue, adjusted EBITDA, and adjusted EPS guidance. The revisions indicate higher expected full-year profitability, with the adjusted EBITDA and adjusted EPS ranges receiving larger increases than the revenue range.

The company does not provide comparable GAAP guidance for adjusted EBITDA or adjusted EPS because it cannot reasonably predict certain adjustments that may affect the reconciliation.

Recent Insider Transactions

A separate insider activity dataset reported 48,962 shares purchased in 29 transactions and 239,368 shares sold in seven transactions over the last six months. That equaled a net sale of 190,406 shares, while reported total insider holdings were approximately 856,310 shares.

The 10 latest reported entries consisted of nine director stock awards and one derivative-security conversion. All were classified as direct ownership, so these records should not be interpreted as 10 open-market trades.

Reported values are reproduced as supplied by the insider transaction dataset and do not establish whether a transaction was an open-market purchase or sale.

Risks Investors Should Monitor

• Labor and staffing costs: Salaries and benefits were the company’s largest operating expense. Difficulty attracting and retaining nurses, therapists, and other healthcare professionals could pressure margins through higher compensation and staffing costs.
• Reimbursement and regulatory changes: Changes to Medicaid or Medicare reimbursement, increased audit activity, and delays or denials in claims processing could reduce revenue or raise provider-related costs.
• Expansion execution and capital intensity: Hospital openings and bed additions require substantial capital. Construction cost inflation, tariffs, material availability, or integration challenges could affect project returns and cash flow.
• Patient demand and operational disruption: Lower demand, infectious disease outbreaks, or system disruptions could reduce patient volumes while also increasing staffing and supply costs.

Summary

Encompass Health’s Q3 2026 results combined higher discharge volume with increased revenue per discharge, while operating costs grew more slowly than revenue. That relationship supported margin expansion, faster EPS and adjusted EBITDA growth, and improved cash generation, leading the company to raise its full-year guidance. The main items to monitor are the durability of same-store volume growth, labor cost control, returns on capacity expansion, and reimbursement conditions.